Tesamorelin vs Sermorelin: FDA Status and Evidence

Compare tesamorelin and sermorelin by mechanism, FDA status, studied population, clinical outcomes, safety evidence, and limits of head-to-head claims.

Tesamorelin and sermorelin both stimulate the growth hormone-releasing hormone receptor, but they are not interchangeable. They differ in molecular design, current regulatory status, studied populations, and the outcomes supported by human trials.

The evidence does not support a general claim that one is “better.” Tesamorelin has current FDA labeling and randomized adult trials for a specific complication of HIV. Sermorelin has historical pediatric growth studies, but the former FDA-approved Geref products are discontinued. No direct human trial comparing the two for the same outcome was identified for this review.

Comparison at a glance

Status is current through August 29, 2026 and refers to the United States.

Question	Tesamorelin	Sermorelin
What is it?	A stabilized analog of the full 44-amino-acid growth hormone-releasing factor sequence	An amidated analog of the first 29 amino acids of growth hormone-releasing hormone
Primary pathway	GHRH receptor → pituitary growth hormone release → downstream IGF-1 signaling	GHRH receptor → pituitary growth hormone release → downstream IGF-1 signaling
Current U.S. regulatory position	FDA-approved tesamorelin products have an indication-specific label for reducing excess abdominal fat in adults with HIV and lipodystrophy	Former Geref products were FDA-approved and later discontinued; no currently marketed FDA-approved sermorelin product was identified at review
Strongest direct human evidence	Randomized, placebo-controlled adult trials in HIV-associated abdominal adiposity	Historical, mostly open-label pediatric studies of growth failure or growth hormone deficiency
Weight-management indication?	No. The current Egrifta WR label says it is not indicated for weight-loss management	No currently marketed FDA-approved product or weight-management indication
Direct comparison with the other compound?	No head-to-head human outcome trial identified	No head-to-head human outcome trial identified

This table compares evidence and regulatory history, not treatment suitability. An FDA approval applies to a specific finished product, formulation, population, and use.

How their mechanisms overlap

Growth hormone-releasing hormone, or GHRH, is produced in the hypothalamus and signals pituitary somatotroph cells to release growth hormone. Growth hormone then contributes to production of insulin-like growth factor 1, or IGF-1, and affects multiple metabolic and growth pathways.

Tesamorelin and sermorelin both use this receptor pathway. Neither is growth hormone itself, and neither should be grouped with ghrelin-receptor agonists such as GHRP-2, GHRP-6, or ipamorelin. The peptide receptor guide explains those pathway differences.

Their shared receptor does not make their clinical evidence transferable. Molecular stability, formulation, exposure, dose selection, population, and trial endpoint all affect what can be concluded about a product.

What tesamorelin evidence establishes

FDA-approved use is narrow

The current Egrifta WR prescribing information describes tesamorelin as a growth hormone-releasing factor analog indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy.

The same label sets important boundaries:

it is not indicated for weight-loss management;
long-term cardiovascular safety has not been established;
it can increase IGF-1;
warnings address malignancy risk, fluid retention, glucose intolerance or diabetes, hypersensitivity, and injection-site reactions; and
Egrifta WR and Egrifta SV have different strengths, preparation instructions, and recommended doses and are not substitutable.

Those limitations contradict common descriptions of tesamorelin as a general fat-loss, bodybuilding, or cardiovascular-prevention peptide.

Randomized trials measured visceral adipose tissue

In a 26-week randomized trial of 412 adults with HIV and abdominal fat accumulation, visceral adipose tissue decreased 15.2% with tesamorelin and increased 5.0% with placebo. Triglycerides also decreased in the tesamorelin group. The trial studied a defined HIV-associated condition, not general obesity (Falutz et al., 2007).

A separate 404-participant trial reported a 10.9% reduction in visceral adipose tissue with tesamorelin versus 0.6% with placebo at six months. Participants who continued tesamorelin maintained a larger reduction at 12 months, while initial improvements were rapidly lost after switching to placebo (Falutz et al., 2010).

Smaller randomized studies investigated liver fat as a research endpoint. A 50-participant trial found reductions in visceral and liver fat over six months, but its authors described the liver-fat result as preliminary and called for research on clinical importance and long-term consequences (Stanley et al., 2014). A later 61-participant trial in people with HIV and nonalcoholic fatty liver disease also reported a greater reduction in hepatic fat fraction with tesamorelin than placebo (Stanley et al., 2019). These studies do not create an FDA-approved liver-disease indication.

What sermorelin evidence establishes

Geref has an approval history, not a current marketed approval

FDA records show that sermorelin acetate was marketed as Geref in diagnostic and pediatric growth-related products. FDA later placed the products in the discontinued section of the Orange Book. In 2013, the agency determined that the products were not withdrawn for reasons of safety or effectiveness (Federal Register notice).

That history requires careful wording. “Previously FDA-approved” does not mean a sermorelin product offered today is FDA-approved. It also does not establish approval for adult growth hormone deficiency, body composition, sleep, recovery, or “anti-aging.”

Sermorelin is now often discussed in the context of compounding. FDA states that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality (FDA compounding questions and answers). A compounded preparation therefore should not be represented as an FDA-approved generic version of Geref.

The clearest efficacy evidence is pediatric and historical

A multicenter open-label study treated 110 previously untreated prepubertal children with growth hormone deficiency for up to one year; 86 were included in the efficacy analysis. Mean height velocity increased from 4.1 centimeters per year at baseline to 8.0 at six months and 7.2 at 12 months (Thorner et al., 1996).

That study supports a historical pediatric growth finding. It does not establish adult fat loss, muscle gain, improved sleep, cognitive benefit, cardiovascular protection, or slowed aging. Those outcomes would require their own controlled human trials.

Why the trial results cannot be ranked

The tesamorelin and sermorelin studies answer different questions:

Evidence feature	Tesamorelin pivotal research	Sermorelin pediatric research
Population	Adults with HIV and excess abdominal fat	Children with growth hormone deficiency or growth failure
Main outcome	Change in visceral adipose tissue	Change in linear growth velocity
Comparator	Placebo in pivotal randomized trials	Primarily baseline change in an open-label study
Treatment era	Late 2000s onward	Primarily late 1980s and 1990s
What remains unknown	General weight-loss benefit, long-term cardiovascular safety, and transfer to populations outside the studied indication	Current finished-product performance and adult body-composition, aging, sleep, and cardiovascular outcomes

Because the populations and outcomes do not overlap, numerical results cannot establish relative potency, effectiveness, or safety. A shorter peptide sequence or a more stable analog also does not, by itself, predict a better clinical result.

Safety evidence should stay product-specific

For tesamorelin, the current FDA label is the most useful starting point because it ties warnings to a reviewed formulation and clinical program. It calls for attention to IGF-1 elevation and glucose status and lists several contraindications and warnings.

For sermorelin, historical Geref studies and labels describe a discontinued finished product. They cannot verify the concentration, purity, sterility, stability, excipients, or clinical performance of a current compounded preparation. This is a quality distinction as well as a regulatory one.

Claims that endogenous growth hormone stimulation makes overdose “impossible,” eliminates off-target effects, or is inherently safer than direct growth hormone are too broad. Physiologic feedback may shape the response, but it does not replace product-specific safety data or clinical monitoring.

Research questions to ask

When evaluating either compound, ask:

What exact product and formulation was studied? Do not treat an active ingredient, compounded preparation, and FDA-approved finished product as equivalent.
Does the population match the claim? Pediatric growth and HIV-associated abdominal fat are not proxies for general adult body composition.
Was the outcome clinically meaningful? A change in GH, IGF-1, visceral fat area, body weight, or height velocity answers a different question.
Was there a control group? Open-label baseline changes provide weaker comparative evidence than randomized placebo-controlled outcomes.
How long was follow-up? Short-term biomarker or imaging changes do not establish long-term cardiovascular, cancer, or metabolic outcomes.
Is the claim based on a shared mechanism or a direct trial? Similar receptor activity does not prove similar benefits or risks.

Frequently asked questions

Is tesamorelin FDA-approved?

Yes, specific tesamorelin products are FDA-approved for a narrow indication: reducing excess abdominal fat in adults with HIV and lipodystrophy. The current label does not approve tesamorelin for general weight management.

Is sermorelin FDA-approved?

The former Geref products were FDA-approved and later discontinued. No currently marketed FDA-approved sermorelin product was identified at this review date. Compounded sermorelin is not FDA-approved.

Which has better evidence for fat loss?

Tesamorelin has randomized evidence for reducing visceral adipose tissue in adults with HIV-associated abdominal fat accumulation. Sermorelin's historical pediatric growth studies did not test that outcome. This difference does not establish tesamorelin as a general weight-loss treatment or prove superiority in another population.

Which has better evidence for growth hormone deficiency?

Historical sermorelin studies directly evaluated growth in children with growth hormone deficiency. Tesamorelin's current approved indication and pivotal evidence concern HIV-associated abdominal fat in adults. Current diagnosis and treatment decisions require indication-specific clinical guidance rather than choosing between these trial programs.